Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: A study of potential oscillatory behaviour and correlations

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Madondo, Mutsa T ^a   Tuyaerts, Sandra ^b   Turnbull, Brit B ^c   Vanderstraeten, Anke ^b   Kohrt, Holbrook ^c   Narasimhan, Balasubramanian ^c   Amant, Frederic ^b   Quinn, Michael ^d   Plebanski, Magdalena ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c STANFORD UNIVERSITY   (United States)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

CRP; Gynaecological malignancies; Inflammation; Teff; Treg

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; MEDROXYPROGESTERONE ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; C REACTIVE PROTEIN BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CELL ISOLATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; LOW DRUG DOSE; MIDDLE AGED; MONONUCLEAR CELL; OVARY CARCINOMA; PERITONEUM TUMOR; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; VERY ELDERLY; CLINICAL TRIAL; FEMALE GENITAL TRACT TUMOR; IMMUNOLOGY; METABOLISM; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84902712334     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-179     Document Type: Article

References (35)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
2. Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012, 58:133-147. 10.1016/j.cyto.2012.01.015, 22349527.
3. Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol 2010, 206:141-157. 10.1677/JOE-10-0072, 20406782.
4. Brannstrom M, Pascoe V, Norman RJ, McClure N. Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. Fertil Steril 1994, 61:488-495.
5. Dahm-Kahler P, Ghahremani M, Lind AK, Sundfeldt K, Brannstrom M. Monocyte chemotactic protein-1 (MCP-1), its receptor, and macrophages in the perifollicular stroma during the human ovulatory process. Fertil Steril 2009, 91:231-239. 10.1016/j.fertnstert.2007.07.1330, 18829011.
6. He YY, Cai B, Yang YX, Liu XL, Wan XP. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 2009, 100:1051-1061. 10.1111/j.1349-7006.2009.01148.x, 19432902.
7. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009, 119:3011-3023. 10.1172/JCI39065, 2752076, 19741298.
8. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR, . Australian Ovarian Cancer Study Group A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012, 72:66-75. 3252703, 22065722, Australian Ovarian Cancer Study Group.
9. Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996, 8:578-585. 10.1006/cyto.1996.0077, 8891439.
10. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 2007, 27:267-272.
11. Young DP, Kushner I, Samols D. Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol 2008, 181:2420-2427. 10.4049/jimmunol.181.4.2420, 18684932.
12. Yoshizaki K. Pathogenic role of IL-6 combined with TNF-alpha or IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases. Adv Exp Med Biol 2011, 691:141-150. 10.1007/978-1-4419-6612-4_15, 21153318.
13. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?. J Transl Med 2009, 7:102. 10.1186/1479-5876-7-102, 2791755, 19948067.
14. Li J, Mo HY, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM, Zheng LM, Qian CN, Zeng YX. Tumor microenvironment MIF directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem 2012, 287:35484-35495. 10.1074/jbc.M112.367532, 3471767, 22893706.
15. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, DeMatteo RP. Regulatory T Cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013, 20:946-955. 10.1245/s10434-012-2668-9, 3740360, 23010736.
16. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354. 10.1093/intimm/dxm014, 17329235.
17. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P. CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177:7398-7405. 10.4049/jimmunol.177.10.7398, 17082659.
18. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949. 10.1038/nm1093, 15322536.
19. Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol 2011, 41:2010-2020. 10.1002/eji.201041205, 3783213, 21491419.
20. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B, Kelleher A, Fazekas-de-St-Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700. 10.1084/jem.20060468, 2118333, 16818676.
21. Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD. Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol 2012, 42:1893-1905. 10.1002/eji.201242444, 22585674.
22. Bollinger T, Leutz A, Leliavski A, Skrum L, Kovac J, Bonacina L, Benedict C, Lange T, Westermann J, Oster H, Solbach W. Circadian clocks in mouse and human CD4+ T cells. PLoS One 2011, 6:e29801. 10.1371/journal.pone.0029801, 3247291, 22216357.
23. Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 2006, 26:1715-1718.
24. Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Terao T. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem 2003, 278:26793-26802. 10.1074/jbc.M212187200, 12743121.
25. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL. Functional characterization of human Cd33+ and Cd11b + myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011, 9:90. 10.1186/1479-5876-9-90, 3128058, 21658270.
26. Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) 2012, 4:958-975.
27. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2325-2333. 10.1210/jc.2009-2564, 2869546, 20207826.
28. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506. 10.4049/jimmunol.0802740, 2810498, 19342621.
29. Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, Lee IJ, Seong J, Ha SJ. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol 2012, 278:76-83. 10.1016/j.cellimm.2012.07.001, 23121978.
30. Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, Whiteside TL. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012, 42:1876-1885. 10.1002/eji.201142347, 3689271, 22585562.
31. Chen ZF, Xu Q, Ding JB, Zhang Y, Du R, Ding Y. CD4 + CD25 + Foxp3+ Treg and TGF-beta play important roles in pathogenesis of Uygur cervical carcinoma. Eur J Gynaecol Oncol 2012, 33:502-507.
32. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012, 13:832-842. 10.1038/ni.2376, 3622453, 22842346.
33. Nunez S, Saez JJ, Fernandez D, Flores-Santibanez F, Alvarez K, Tejon G, Ruiz P, Maldonado P, Hidalgo Y, Manriquez V, Bono MR, Rosemblatt M, Sauma D. Th17 cells contribute to anti-tumor immunity and promote the recruitment of th1 cells to the tumor. Immunology 2013, 139:61-71. 10.1111/imm.12055, 3634539, 23278668.
34. Gao Y, Whitaker-Dowling P, Griffin JA, Bergman I. Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells. Cancer Gene Ther 2012, 19:282-291. 10.1038/cgt.2011.90, 3307905, 22240921.
35. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010, 207:637-650. 10.1084/jem.20091918, 2839156, 20156971.